Articles By Rob Wright, Chief Editor 2011-2021
-
![Can China Be Trusted?]( "Can China Be Trusted?")
Can China Be Trusted?10/1/2018Rob Wright discusses China’s history of intellectual property (IP) theft, and wonders if the government-sponsored 10-year initiative, Made in China 2025 (MIC 2025), could exacerbate the problem.
-
![Netherlands_Windmill_tulips_450x300]( "The Future Of Biopharma — Netherlands Style")
The Future Of Biopharma — Netherlands Style9/18/2018Rob Wright shares what he looks forward to learning about during an upcoming press tour of the Netherlands, beyond the fact that the European Medicines Agency (EMA) will be relocating there in 2019.
-
![Rob Wright_2017_450x300]( "Nothing Ventured, Nothing Learned")
Nothing Ventured, Nothing Learned9/3/2018This month’s issue, like many before, features a variety of executives who have demonstrated a willingness to take significant risks.
-
![TonyColes_450x300]( "One-On-One With Tony Coles, CEO Of Yumanity Therapeutics")
One-On-One With Tony Coles, CEO Of Yumanity Therapeutics9/3/2018Six months after Amgen acquired Onyx Pharmaceuticals, Tony Coles, M.D. was pondering his next move. The former Onyx CEO wasn’t planning to lead another pharma company so soon … but then he got a phone call.
-
![learning-never-ends-road]( "What Mylan Could Learn About Accountability")
What Mylan Could Learn About Accountability8/31/2018Mylan’s inability to adequately supply its EpiPen during the 2018 back-to-school time is the latest example of corporate leadership lacking accountability.
-
![GMO Tomato Injection]( "Are Genetically Modified Organisms (GMO) A Blessing Or A Curse?")
Are Genetically Modified Organisms (GMO) A Blessing Or A Curse?8/27/2018A question about GMOs submitted to our editorial board leads us to look more closely into this issue and how it affects the pharma industry.
-
![Amir Katali]( "Why A Biopharma Executive Founded A Game-Changing Conference")
Why A Biopharma Executive Founded A Game-Changing Conference8/20/2018Amir Kalali, M.D., former global head of Quintiles (now IQVIA) neuroscience center of excellence, provides insight on why he decided to found an educational conference, The CNS Summit, while still working as a biopharmaceutical industry executive.
-
![person on top of mountain]( "Is It Possible For A Biopharmaceutical Executive To Transcend Their Industry?")
Is It Possible For A Biopharmaceutical Executive To Transcend Their Industry?8/9/2018What current biopharma leaders have the potential to “transcend” beyond this industry? Chief Editor Rob Wright gives his top three choices.
-
![Rob Wright_2017_450x300]( "Is Biopharma Ready For AI?")
Is Biopharma Ready For AI?8/2/2018Is the pharma industry ready to move beyond the buzz regarding terms like terms like AI, digital health, and machine learning (ML)?
Rob Wright
Rob Wright was chief editor of Life Science Leader magazine from 2011-2021. Prior to joining the publication, he spent nearly 20 years in the pharmaceutical industry. During his industry career, Wright conducted well over 1,000 presentations and roundtable discussions, including the facilitation of FDA-mandated clinical training programs for hundreds of licensed healthcare providers. He has chaired, moderated, and served as a speaker at industry and academic conferences, and served as co-chair for the 2015 and 2018 BIO International conference’s educational planning committee. Wright’s 500+ published articles have appeared in peer-reviewed academic journals, B2B magazines and online publications. He received a B.S. in Business Administration from Indiana University of Pennsylvania, MBA with distinction from Gannon University, and completed his doctoral coursework in marketing at Cleveland State University. He is a member of international business honor societies Sigma Beta Delta and Beta Gamma Sigma. He can be followed on Twitter @RfwrightLSL